Nkarta NKTX
NASDAQ NKTX
$2.58 +0.02 (+0.78%)
At close: Oct 2, 2026 · 4:00 PM EDT

Nkarta (NKTX) Return on Sales [ROS] (2019 - 2020)

Updated

Nkarta's Return on Sales [ROS] was -2192251.69% in Q3 2020.

Analysis

Nkarta (NKTX) Return on Sales [ROS] (2019 - 2020) Analysis & Trends

For FY2019, Return on Sales [ROS] at Nkarta came in at -19433.91%.

  • The Q3 2020 figure marks the highest quarterly Return on Sales [ROS] since Q2 2019.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn 51.16%
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn 28.21%
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn 37.86%
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn -3.52%
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn 32.97%
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn 20.57%
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn 34.95%
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn -133.21%
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn 28.37%
10 Nkarta 184.79 Mn 184.79 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2020 -2,192,251.69%
Jun 30, 2019 -202,375.30%
API Access

Nkarta Return on Sales [ROS] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=NKTX&period=max&api_key=YOUR_API_KEY